An Update on Anti-Vascular Endothelial Growth Factor Treatment for Retinopathy of Prematurity.

IF 1.2 Q3 OPHTHALMOLOGY

Journal of Current Ophthalmology Pub Date : 2023-12-21 eCollection Date: 2023-04-01 DOI:10.4103/joco.joco_38_23

M Hossein Nowroozzadeh, Elham Sadeghi, Hossein Shahriari-Garaee, Mohammad Reza Badie, Javad Banihashemi, Sunir J Garg

{"title":"An Update on Anti-Vascular Endothelial Growth Factor Treatment for Retinopathy of Prematurity.","authors":"M Hossein Nowroozzadeh, Elham Sadeghi, Hossein Shahriari-Garaee, Mohammad Reza Badie, Javad Banihashemi, Sunir J Garg","doi":"10.4103/joco.joco_38_23","DOIUrl":null,"url":null,"abstract":"Purpose: To present updated information on the role of anti-vascular endothelial growth factor (anti-VEGF) therapy for treating retinopathy of prematurity (ROP).Methods: We searched through PubMed and Scopus databases using the keywords of this article and gathered relevant published articles from the year 2005 to December 2022. The selected articles were classified and summarized, and reasonable conclusions were made accordingly.Results: Considering the current evidence, anti-VEGF agents are superior to laser therapy for the initial treatment of type 1 ROP in zone 1 or posterior zone 2. However, there is a substantial risk of reactivation or persistent avascular retina after solo treatment with anti-VEGFs, and many cases may require laser therapy within the following weeks or months. Thus, vigilant follow-up examinations are mandatory.Conclusions: The role of anti-VEGF agents in the treatment of ROP is indispensable. However, future studies are required to improve indications and dosage and determine long-term ocular and systemic safety.","PeriodicalId":15423,"journal":{"name":"Journal of Current Ophthalmology","volume":null,"pages":null},"PeriodicalIF":1.2000,"publicationDate":"2023-12-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10795819/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Current Ophthalmology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.4103/joco.joco_38_23","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2023/4/1 0:00:00","PubModel":"eCollection","JCR":"Q3","JCRName":"OPHTHALMOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Purpose: To present updated information on the role of anti-vascular endothelial growth factor (anti-VEGF) therapy for treating retinopathy of prematurity (ROP).

Methods: We searched through PubMed and Scopus databases using the keywords of this article and gathered relevant published articles from the year 2005 to December 2022. The selected articles were classified and summarized, and reasonable conclusions were made accordingly.

Results: Considering the current evidence, anti-VEGF agents are superior to laser therapy for the initial treatment of type 1 ROP in zone 1 or posterior zone 2. However, there is a substantial risk of reactivation or persistent avascular retina after solo treatment with anti-VEGFs, and many cases may require laser therapy within the following weeks or months. Thus, vigilant follow-up examinations are mandatory.

Conclusions: The role of anti-VEGF agents in the treatment of ROP is indispensable. However, future studies are required to improve indications and dosage and determine long-term ocular and systemic safety.

查看原文本刊更多论文

抗血管内皮生长因子治疗早产儿视网膜病变的最新进展。

目的：介绍抗血管内皮生长因子（anti-VEGF）疗法在治疗早产儿视网膜病变（ROP）中所起作用的最新信息：我们使用本文的关键词在 PubMed 和 Scopus 数据库中进行了检索，收集了 2005 年至 2022 年 12 月期间发表的相关文章。对所选文章进行分类和总结，并据此得出合理结论：考虑到目前的证据，抗血管内皮生长因子药物在初始治疗 1 区或后 2 区的 1 型 ROP 时优于激光治疗。然而，单用抗血管内皮生长因子治疗后，视网膜再激活或持续性无血管视网膜的风险很大，许多病例可能需要在接下来的几周或几个月内进行激光治疗。因此，必须进行警惕性随访检查：结论：抗血管内皮生长因子药物在治疗 ROP 中的作用不可或缺。结论：抗血管内皮生长因子药物在治疗视网膜病变中的作用是不可或缺的，但今后还需要进行研究，以改进适应症和剂量，并确定长期眼部和全身安全性。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Journal of Current Ophthalmology OPHTHALMOLOGY-

CiteScore

2.50

自引率

6.70%

发文量

审稿时长

8 weeks

期刊介绍： Peer Review under the responsibility of Iranian Society of Ophthalmology Journal of Current Ophthalmology, the official publication of the Iranian Society of Ophthalmology, is a peer-reviewed, open-access, scientific journal that welcomes high quality original articles related to vision science and all fields of ophthalmology. Journal of Current Ophthalmology is the continuum of Iranian Journal of Ophthalmology published since 1969.